Skip to content

Monosomy 9q22 3 C3711390

Published: July 22, 2026Updated: August 20, 2026

A rare chromosomal deletion where part of chromosome 9 is missing, affecting development and organ formation. Severity varies; management focuses on symptom treatment and developmental support.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q89.9
ICD-11
LA00.0
Body system
congenital
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Developmental delay

(neurological)

Generalized symptoms

(congenital)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Craniosynostosis

(musculoskeletal)

Intellectual disability

(neurological)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Oncogenomic Surveillance Program

Enhanced monitoring for tumor predisposition associated with 9q22.3 deletions, including regular skin examinations and neuroimaging as clinically indicated for potential growths.

monitoring
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Endocrine and Growth Assessment

Comprehensive endocrine evaluation including growth hormone studies, thyroid function, and puberty assessment with appropriate intervention for deficiencies.

procedure

Additional treatment options

Corrective Surgical Interventions

Surgical management of structural abnormalities including craniofacial, skeletal, or visceral anomalies identified through diagnostic imaging.

surgical

Nutritional Support and Feeding Optimization

Nutritional assessment and intervention for feeding difficulties, growth failure, or gastrointestinal issues common with this chromosomal region deletion.

dietary

Family Support and Resource Coordination

Connection to support organizations, respite care services, and family support programs designed for families affected by rare chromosomal conditions.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Monosomy 9q22 3 C3711390?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Monosomy 9q22 3 C3711390. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy